Crown ElectroKinetics (NASDAQ:CRKN) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.09) by 322.22 percent.
Baird Initiates Coverage On Ambrx Biopharma with Outperform Rating, Announces Price Target of $16
Baird analyst Joel Beatty initiates coverage on Ambrx Biopharma (NYSE:AMAM) with a Outperform rating and announces Price Target of $16.